Drugs / Hydrogen Peroxide
Hydrogen Peroxide
also known as
A-101 · H2O2 · ActiveOxy · Crystacide · Eskata · Hioxyl · HP40 · Hydrogen peroxide solution · +10 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ESKATA | — | 2017-12-14 | fda.gov ↗ |
Trials 46
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05669560 | Jan 2023 → May 2027 | chronic periodontitis, type 2 diabetes mellitus | University of Oklahoma | Withdrawn | No outcome recorded |
| Phase 0 | NCT05024760 | Jul 2022 → Nov 2025 overdue | mucositis, periodontitis, prosthesis-related infectious disease | Madigan Army Medical Center | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05570422 | Mar 2026 → Jan 2027 expected | cervical cancer | Kortuc, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06404190 | May → Aug 2023 | periodontitis | Krishnadevaraya College of Dental Sciences & Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02757651 | Jan 2017 → Nov 2020 | female breast carcinoma | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 28 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07713329 | Mar → Jun 2026 | pleural empyema, respiratory tract infectious disorder | Delta University for Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT04929535 | Sep 2022 → Aug 2023 | basal cell carcinoma, skin squamous cell carcinoma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 2 | NCT04409873 | Mar 2021 → Sep 2022 | COVID-19, disorder of pharynx | University of California, San Francisco | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT03946202 | Jun 2020 → Aug 2028 expected | breast cancer | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03210337 | Aug 2017 → Mar 2018 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03278028 | Jul 2017 → Mar 2018 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03224598 | Jun 2017 → Jan 2019 | dermatosis papulosa nigra | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02669862 | Dec 2015 → Sep 2016 | common wart | Aclaris Therapeutics, Inc. | Completed | Met primary |
| Phase 311 trials · 2 met primary | ||||||
| Phase 3 | NCT07830979 | Sep 2026 → Sep 2027 expected | plantar wart | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07276672 | Nov 2025 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT06957249 | Apr → May 2025 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT07351370 | Jan → Jul 2022 | periodontal disorder | Dental School | Completed | No outcome recorded |
| Phase 3 | NCT04438434 | Jun → Jul 2020 | impacted teeth, multiple | University of Milan | Unknown | No outcome recorded |
| Phase 3 | NCT03812510 | Feb → Nov 2019 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03687372 | Sep 2018 → Jun 2019 | common wart | Aclaris Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT03691831 | Sep 2018 → Apr 2019 | common wart | Aclaris Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT02667275 | Jan → Oct 2016 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02667288 | Jan → Oct 2016 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00978861 | Oct 2008 → Jun 2009 | — | JDC Tech | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06045429 | May 2024 → Jun 2025 overdue | — | Charles University, Czech Republic | Recruiting | No outcome recorded |
| Phase 4 | NCT04659928 | Jul 2021 → May 2024 | COVID-19 | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT04407910 | Sep 2018 → Mar 2019 | dental fluorosis | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT03514797 | Apr → Jun 2018 | tooth disorder | André Luis Faria e Silva | Completed | No outcome recorded |
| Phase 4 | NCT03262701 | Apr 2018 → Feb 2021 | chronic periodontitis | Loma Linda University | Terminated | No outcome recorded |
| Phase 4 | NCT03487588 | Mar → Nov 2018 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase not applicable16 trials · 1 missed | ||||||
| — | NCT07534865 | May 2026 → Dec 2028 expected | common wart | First Hospital of China Medical University | Recruiting | No outcome recorded |
| — | NCT07565350 | Oct 2025 → Oct 2027 expected | common wart | First Hospital of China Medical University | Recruiting | No outcome recorded |
| — | NCT07031388 | Jul → Sep 2025 | gingival disorder | Ramziyah Hayder Bakr | Completed | No outcome recorded |
| — | NCT07486245 | Mar → Nov 2025 | pulpitis | CMH Multan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06904118 | Jun → Dec 2024 | dentin sensitivity | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT07287956 | Feb 2024 → Jul 2025 | periodontal disorder | King Abdullah University Hospital | Completed | No outcome recorded |
| — | NCT06030492 | Jan → Sep 2023 | placenta accreta | Cairo University | Unknown | No outcome recorded |
| — | NCT06812065 | Dec 2022 → Dec 2026 expected | common wart | First Hospital of China Medical University | Recruiting | No outcome recorded |
| — | NCT04341688 | Dec 2021 → Jun 2022 | COVID-19 | Aga Khan University | Unknown | No outcome recorded |
| — | NCT04723446 | May → Oct 2021 | COVID-19 | Queen Mary University of London | Completed | No outcome recorded |
| — | NCT04733196 | Oct → Dec 2020 | gingivitis | Plovdiv Medical University | Completed | No outcome recorded |
| — | NCT04707742 | Jun 2020 → Sep 2021 | COVID-19 | FISABIO Foundation | Completed | Missed primary |
| — | NCT03194984 | May 2017 → Jan 2018 | — | Federal University of Uberlandia | Completed | No outcome recorded |
| — | NCT02816593 | Aug 2015 → Jul 2017 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| — | NCT02603354 | Mar → Apr 2015 | tooth disorder | University of Chile | Completed | No outcome recorded |
| — | NCT03217994 | Jan 2015 → Dec 2016 | tooth disorder | University of Chile | Completed | No outcome recorded |
| Comparator or background therapy27 trials | ||||||
| Phase 0 | NCT03678012 Comparator | Jun → Aug 2018 | dental caries | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT03434782 Background | Apr → Nov 2017 | dentin sensitivity | Federal University of Pará | Completed | No outcome recorded |
| Phase 1 | NCT03044171 Background | Aug 2016 → Jan 2017 | dentin sensitivity | Federal University of Pará | Completed | No outcome recorded |
| Phase 1 | NCT01008111 Comparator | Oct 2009 → Apr 2013 | — | Wake Forest University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01986920 Comparator | Oct 2013 → Feb 2014 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04584684 Comparator | Dec 2020 → Oct 2021 | COVID-19 | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT04717063 Comparator | Nov → Dec 2020 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 2 | NCT04626778 Comparator | Oct → Dec 2020 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 2 | NCT03536637 Background | May → Dec 2018 | acne | Dermata Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03148691 Comparator | May 2017 → Feb 2018 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02260180 Comparator | Oct 2014 → Mar 2015 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02160626 Comparator | Jun → Dec 2014 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05198180 Comparator | Feb → Jun 2022 | plantar wart | Sohag University | Unknown | No outcome recorded |
| Phase 3 | NCT02935114 Comparator | May → Jun 2016 | dentin sensitivity | Federal University of Sergipe | Completed | No outcome recorded |
| Phase 3 | NCT02667236 Comparator | Jan → Oct 2016 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT04721457 Comparator | Jan → Mar 2021 | COVID-19 | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT04603794 Comparator | Oct → Nov 2020 | COVID-19 | Ohio State University | Unknown | No outcome recorded |
| Phase 4 | NCT03163069 Background | Jan → Jul 2017 | tooth disorder | Fujian Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03019224 Background | Jan → Apr 2016 | dentin sensitivity | University of Campinas, Brazil | Completed | No outcome recorded |
| — | NCT06884813 Background | Mar 2025 → May 2026 overdue | — | King Abdullah University Hospital | Recruiting | No outcome recorded |
| — | NCT07675278 Comparator | Feb 2024 → Jan 2025 | tonsillitis | Rawalpindi Medical College | Completed | No outcome recorded |
| — | NCT06949176 Background | Dec 2023 → Dec 2024 overdue | periapical periodontitis | National and Kapodistrian University of Athens | Active not recruiting | No outcome recorded |
| — | NCT05569590 Background | May → Dec 2021 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| — | NCT03656588 Comparator | Apr 2018 → Jan 2019 | bacterial infectious disease | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT03412071 Comparator | Dec 2017 → Dec 2019 | — | University of Toronto | Unknown | No outcome recorded |
| — | NCT02383992 Comparator | Oct 2015 → Oct 2019 | — | Northwestern University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02067715 Background | Feb 2014 → May 2015 | tooth disorder | Federal University of Sergipe | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 23
| Date | Issuer | Release |
|---|---|---|
| 2026-05-14 | Kortuc, Inc. | Results KORTUC Basic Research Published in Clinical and Translational Radiation Oncology kortuc.com ↗
Specifically, the study showed that KORTUC promoted immunogenic cell death, preserved T-cell function within tumors, and selectively reduced immunosuppressive M2-like macrophages. |
| 2025-01-07 | Kortuc, Inc. | Results KORTUC’s Basic Research Published in The Green Journal kortuc.com ↗
The study, titled “Revisiting Hydrogen Peroxide as a Radiosensitizer for Solid Tumor Cells,” demonstrates that KORTUC suppresses oxygen consumption in hypoxic tumor cells via mitochondrial pathways, restores oxygen levels, and significantly enhances the effects of radiotherapy. |
| 2024-10-12 | Kortuc, Inc. | Results A new article of KORTUC (KRC-01) was published in ”BJC Reports” kortuc.com ↗
This article demonstrates tumour reoxygenation by KORTUC in vitro/in vivo model, and shows its promising potential of KORTUC for the treatment of hypoxic tumors across various cancer types. |
| 2023-05-29 | Kortuc, Inc. | Results KRC-01’s new basic research result will be presented at International Wolfsberg Meeting kortuc.com ↗
In this study, it was shown that the radiosensitizing effect of H2O2 under hypoxic conditions can be attributed to the inhibition of cellular respiration through a complex I (exist on the inner mitochondrial membrane) blockade, in addition to reoxygenating cells. |
| 2023-04-13 | Kortuc, Inc. | Results KRC-01’s new basic research result will be presented at ESTRO2023 kortuc.com ↗
In this study, it was shown that the radiosensitizing effect of H2O2 under hypoxic conditions can be attributed to the inhibition of cellular respiration through a complex I (exist on the inner mitochondrial membrane) blockade, in addition to reoxygenating cells. |
| 2022-09-29 | Kortuc, Inc. | Results KORTUC’s new basic research result will be presented at BACR2022 kortuc.com ↗
In this study, it was shown for the first time that the radiosensitizing effect of H2O2 under hypoxic conditions can be attributed to the inhibition of cellular respiration, in addition to reoxygenating cells. |
| 2019-10-24 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1) aclaristx.com ↗
A-101 45% met the primary and all secondary efficacy endpoints, achieving clinically meaningful and statistically significant clearance of common warts. |
| 2019-09-16 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) aclaristx.com ↗
A-101 45% Topical Solution met the primary and all secondary efficacy endpoints, achieving clinically and statistically significant clearance of common warts. |
| 2019-02-28 | Aclaris Therapeutics, Inc. | Regulatory Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg aclaristx.com ↗
Aclaris also has received approval to market the medicine in the United Kingdom , Iceland , Belgium , and Finland . |
| 2018-06-12 | Aclaris Therapeutics, Inc. | Results Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses aclaristx.com ↗ |
| 2018-03-29 | Aclaris Therapeutics, Inc. | Results Topical Solution May Be Less Toxic Option for Patients with Noncancerous Skin Growth aclaristx.com ↗
The findings were recently published in the Journal of the American Academy of Dermatology. |
| 2018-03-19 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts aclaristx.com ↗
Over the 3-month post-treatment follow-up period, greater improvements in common wart reduction and clearance vs. placebo were observed among subjects treated with A-101 45%. |
| 2018-01-08 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts aclaristx.com ↗
A-101 45% met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of common warts. |
| 2017-12-15 | Aclaris Therapeutics, Inc. | Regulatory Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs) aclaristx.com ↗
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. |
| 2017-09-19 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis aclaristx.com ↗
In the trial, A-101 achieved statistical significance in clearing SK lesions on the face in a dose-related fashion. |
| 2017-08-03 | Aclaris Therapeutics, Inc. | Regulatory Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis aclaristx.com ↗ |
| 2017-05-09 | Aclaris Therapeutics, Inc. | Regulatory FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition aclaristx.com ↗
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) A-101 40% topical solution (A-101 40%), an investigational drug, for the potential treatment of seborrheic keratosis (SK), a common skin condition. |
| 2017-02-27 | Aclaris Therapeutics, Inc. | Regulatory Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition aclaristx.com ↗
today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). |
| 2016-11-15 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition aclaristx.com ↗ |
| 2016-08-18 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts aclaristx.com ↗ |
| 2015-03-17 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor aclaristx.com ↗
Aclaris Therapeutics, Inc. today announced statistically significant results from a Phase 2 clinical trial of its lead drug candidate, A-101. |
| 2015-01-27 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor aclaristx.com ↗
Results from the study showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. |
| 2014-06-30 | Aclaris Therapeutics, Inc. | Results Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor aclaristx.com ↗
Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company’s lead drug, A-101. |
All press releases naming this drug 35 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 75 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydrogen Peroxide | “A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101(Hydrogen Peroxide) Topical Solution in Subjects With...” NCT03148691 ↗62“An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage” NCT03487588 ↗ “Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.” NCT03224598 ↗ “KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.” NCT05570422 ↗ “Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.” NCT03044171 ↗ “Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.” NCT03434782 ↗ “Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth” NCT03163069 ↗ “In one group, the hemiarcade was bleached with 37.5% hydrogen peroxide (Polaoffice + 37.5% SDI Limited, Bayswater, Australia).” NCT03217994 ↗ “Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide” NCT07276672 ↗ “A 40% hydrogen peroxide bleaching agent was applied twice for 15 min for the in-office bleaching treatment.” PMID 34145478 ↗ Jun 2021 “In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.” NCT03514797 ↗ |
| Known as | A-101 | “An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage” NCT03487588 ↗11“Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.” NCT03224598 ↗ “A-101 45% (hydrogen peroxide 45% topical solution)” NCT03691831 ↗ |
| Known as | ActiveOxy | “1% Hydrogen peroxide (HP® by Karachi Chemicals Products Inc./ ActiveOxy® by Boumatic Inc.)” PMID 32928313 ↗ Sep 2020 |
| Known as | Crystacide | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Eskata | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | H2O2 | “Hydrogen peroxide (H2O2): Helps remove debris physically and has some antimicrobial activity, though its efficacy against bacteria is less well established.” NCT07486245 ↗6“Vigorously rinse with 15 ml of the 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK) for 30 s” NCT04721457 ↗ “rinsing with: Group 1-0.2% Chlorhexidine digluconate (CHX); Group 2-1.5% Hydrogen peroxide (H2O2);” PMID 37542087 ↗ Aug 2023 “Hydrogen peroxide (H2O2) is a commonly used disinfectant for skin debridement.” NCT06812065 ↗ “hydrogen peroxide (H2O2) and hyaluronic acid (HA) combination formulation” PMID 39012233 ↗ Jul 2024 “Intrapleural Hydrogen Peroxide (H_2O_2)” NCT07713329 ↗ “Hydrogen Peroxide ( H2O2)” NCT06030492 ↗ |
| Known as | Hioxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | HP40 | “40% (w/w) hydrogen peroxide topical solution (HP40).” PMID 30365590 ↗ Oct 2018 |
| Known as | Hydrogen peroxide solution | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Hyrogen peroxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | NSC-19892 | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Opalescence Boost PF 40% | “Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth” NCT03163069 ↗ |
| Known as | Oroxid | “3% hydrogen peroxide (Oroxid®) versus standard of care (0.2% chlorhexidine digluconate)” NCT06045429 ↗ |
| Known as | Oximen 3% | “Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain).” NCT04707742 ↗ |
| Known as | Oxydol | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Perio Gel | “administer 1.7% hydrogen peroxide gel (Perio Gel®, QNT Anderson, Bismarck, ND) deep into the periodontal pocket” NCT05669560 ↗ |
| Known as | Peroxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Whiteness HP | “The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen...” NCT03019224 ↗ |
| Known as | Whiteness HP Maxx | “A 35% hydrogen peroxide based bleaching agent (Whiteness HP Maxx, FGM, Joinville, SC, Brazil) will be mixed and applied on the vestibular surface of teeth, in the ratio of 1...” NCT02935114 ↗ |
| Action | Inhibit | “helps in reducing bacterial load” NCT07031388 ↗ |
| Modality | Small molecule | — CHEMBL71595 ↗ |
| Route | Topical | “when applied topically up to 2 times to SK target lesions on the face.” NCT02260180 ↗ |